Bionomics Results Presentation Deck

PREVAIL is expected to enable late-stage development of BNC210 in SAD Options for SUDS-based late-stage endpoints were identified and will be discussed with FDA Questions that PREVAIL Addressed: 1 2 3 4 5 6 7 25 Efficacy Primary Outcome Dose Response Patient Population Safety Pharmacokinetics Overall Design Is BNC210 is pharmacologically active and potentially efficacious Analysis of SUDS by combination of phases of the public speaking task delivered stronger trends that reached significance in the combined dose arm No dose separation was observed - BNC210 225 mg will be tested in late-stage trials Focus on younger adults and potentially adolescents which make up most of the SAD population in the real word. Safety and tolerability profile is favorable and compatible with a non-sedating anxiolytic The new BNC210 tablet formulation delivers a PK profile with rapid onset of effect for acute treatment of social anxiety PREVAIL was completed in less than a year. The SAD Task performed as expected Bionomics

View entire presentation